US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Articles published by Repare Therapeutics Inc.

< Previous 1 2 3 Next >
News headline image
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Leadership Transitions
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
News headline image
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
< Previous 1 2 3 Next >